BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioAxone Therapeutic Inc. Release: Cethrin(R) Receives Orphan Drug Status


12/12/2005 12:09:25 PM

MONTREAL, Dec. 12 /PRNewswire/ - BioAxone Therapeutic Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to its drug candidate Cethrin(R), which is currently in a phase I/IIa clinical trial for patients with acute thoracic and cervical spinal cord injuries.

"The Orphan Drug Status, granted for rare diseases afflicting less than 200,000 patients per year in the U.S., provides BioAxone with considerable strategic advantages for accelerating the development of its lead drug candidate Cethrin(R) by extending its patent protection, reducing clinical development costs and facilitating regulatory filings in other countries" said Dr. Frank Bobe, President and Chief Executive Officer of BioAxone. "Recruitment for our phase I/IIa trial is on schedule and completion is expected by June of 2006".

There is currently no effective treatment for acute spinal cord injury, a condition that can lead to complete and permanent loss of sensory and motor functions and require life-long specialized care for the vast majority of patients. In addition to creating significant health care costs, spinal cord injury has a dramatic impact on the quality of life of patients and those who care for them. At BioAxone, in vitro as well as in vivo studies have demonstrated the neuro-protective and neuro-regenerative properties of Cethrin(R), underscoring the potential benefits of this treatment for patients with acute spinal cord injury.

About BioAxone

BioAxone Therapeutic Inc. is a privately owned neuroscience company specializing in the development and commercialization of proprietary technologies that target Rho GTPase signaling.

BioAxone is a product-driven company, with one product currently in clinical development for the treatment of acute spinal cord injury and several candidate products in preclinical phase for the treatment of macular degeneration and glaucoma. The Company has proven expertise in recombinant protein drug development and has a focused small molecule program. BioAxone was established in April 2000 and is headquartered in Montreal, Canada.

BIOAXONE THERAPEUTIC INC.

CONTACT: Dr Frank Bobe, President and CEO, BioAxone Therapeutic Inc.,(514) 282-9990, info@bioaxone.com; www.bioaxone.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES